Vaccine Candidates against Arenavirus Infections

Takeshi Saito; Rachel A. Reyna; Satoshi Taniguchi; Kirsten Littlefield; Slobodan Paessler; Junki Maruyama

doi:10.3390/vaccines11030635

Vaccine Candidates against Arenavirus Infections

Takeshi Saito, Rachel A. Reyna, Satoshi Taniguchi, Kirsten Littlefield, Slobodan Paessler, Junki Maruyama

Pathology

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

The viral family Arenaviridae contains several members that cause severe, and often lethal, diseases in humans. Several highly pathogenic arenaviruses are classified as Risk Group 4 agents and must be handled in the highest biological containment facility, biosafety level-4 (BSL-4). Vaccines and treatments are very limited for these pathogens. The development of vaccines is crucial for the establishment of countermeasures against highly pathogenic arenavirus infections. While several vaccine candidates have been investigated, there are currently no approved vaccines for arenavirus infection except for Candid#1, a live-attenuated Junin virus vaccine only licensed in Argentina. Current platforms under investigation for use include live-attenuated vaccines, recombinant virus-based vaccines, and recombinant proteins. We summarize here the recent updates of vaccine candidates against arenavirus infections.

Original language	English (US)
Article number	635
Journal	Vaccines
Volume	11
Issue number	3
DOIs	https://doi.org/10.3390/vaccines11030635
State	Published - Mar 2023

Keywords

Junin virus
Lassa virus
arenavirus
vaccine
virus attenuation

ASJC Scopus subject areas

Immunology
Pharmacology
Drug Discovery
Infectious Diseases
Pharmacology (medical)

Access to Document

10.3390/vaccines11030635

Cite this

@article{44f33dd3a532492f8f97c4a2f4463bb8,

title = "Vaccine Candidates against Arenavirus Infections",

abstract = "The viral family Arenaviridae contains several members that cause severe, and often lethal, diseases in humans. Several highly pathogenic arenaviruses are classified as Risk Group 4 agents and must be handled in the highest biological containment facility, biosafety level-4 (BSL-4). Vaccines and treatments are very limited for these pathogens. The development of vaccines is crucial for the establishment of countermeasures against highly pathogenic arenavirus infections. While several vaccine candidates have been investigated, there are currently no approved vaccines for arenavirus infection except for Candid#1, a live-attenuated Junin virus vaccine only licensed in Argentina. Current platforms under investigation for use include live-attenuated vaccines, recombinant virus-based vaccines, and recombinant proteins. We summarize here the recent updates of vaccine candidates against arenavirus infections.",

keywords = "Junin virus, Lassa virus, arenavirus, vaccine, virus attenuation",

author = "Takeshi Saito and Reyna, {Rachel A.} and Satoshi Taniguchi and Kirsten Littlefield and Slobodan Paessler and Junki Maruyama",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = mar,

doi = "10.3390/vaccines11030635",

language = "English (US)",

volume = "11",

journal = "Vaccines",

issn = "2076-393X",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "3",

}

TY - JOUR

T1 - Vaccine Candidates against Arenavirus Infections

AU - Saito, Takeshi

AU - Reyna, Rachel A.

AU - Taniguchi, Satoshi

AU - Littlefield, Kirsten

AU - Paessler, Slobodan

AU - Maruyama, Junki

PY - 2023/3

Y1 - 2023/3

N2 - The viral family Arenaviridae contains several members that cause severe, and often lethal, diseases in humans. Several highly pathogenic arenaviruses are classified as Risk Group 4 agents and must be handled in the highest biological containment facility, biosafety level-4 (BSL-4). Vaccines and treatments are very limited for these pathogens. The development of vaccines is crucial for the establishment of countermeasures against highly pathogenic arenavirus infections. While several vaccine candidates have been investigated, there are currently no approved vaccines for arenavirus infection except for Candid#1, a live-attenuated Junin virus vaccine only licensed in Argentina. Current platforms under investigation for use include live-attenuated vaccines, recombinant virus-based vaccines, and recombinant proteins. We summarize here the recent updates of vaccine candidates against arenavirus infections.

AB - The viral family Arenaviridae contains several members that cause severe, and often lethal, diseases in humans. Several highly pathogenic arenaviruses are classified as Risk Group 4 agents and must be handled in the highest biological containment facility, biosafety level-4 (BSL-4). Vaccines and treatments are very limited for these pathogens. The development of vaccines is crucial for the establishment of countermeasures against highly pathogenic arenavirus infections. While several vaccine candidates have been investigated, there are currently no approved vaccines for arenavirus infection except for Candid#1, a live-attenuated Junin virus vaccine only licensed in Argentina. Current platforms under investigation for use include live-attenuated vaccines, recombinant virus-based vaccines, and recombinant proteins. We summarize here the recent updates of vaccine candidates against arenavirus infections.

KW - Junin virus

KW - Lassa virus

KW - arenavirus

KW - vaccine

KW - virus attenuation

UR - http://www.scopus.com/inward/record.url?scp=85152067508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85152067508&partnerID=8YFLogxK

U2 - 10.3390/vaccines11030635

DO - 10.3390/vaccines11030635

M3 - Review article

C2 - 36992218

AN - SCOPUS:85152067508

SN - 2076-393X

VL - 11

JO - Vaccines

JF - Vaccines

IS - 3

M1 - 635

ER -

Vaccine Candidates against Arenavirus Infections

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this